Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation
Artificial Organs · 2025
DOI: 10.1111/aor.14885 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Iris Feng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heparin, Anticoagulants, Factor Xa Inhibitors. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
No clear guidelines exist for perioperative anticoagulation management after durable left ventricular assist device insertion. In this study, we sought to compare outcomes between anti‐factor Xa (FXa) and activated partial thromboplastin time (aPTT) in monitoring unfractionated heparin (UFH) dosing after HeartMate 3 (HM3) insertion.
Methods
This is a single‐center retrospective review of patients who received UFH after HM3 insertion between 01/2020–12/2022. Post‐operative UFH dose was titrated by aPTT goal 45–60 sec ( n = 53) or FXa goal 0.1–0.2 U/mL ( n = 59). Baseline differences between cohorts were balanced by inverse probability treatment weighting.
Results
At baseline, unadjusted FXa patients were more likely to be white (47.5% vs. 35.8%, p < 0.001), INTERMACS 1–2 (69.5% vs. 47.2%, p = 0.013), have history of coronary artery disease (66.1% vs. 43.4%, p = 0.026), and lower eGFR (54.1 vs. 63.7 mL/min/1.73 m 2 , p = 0.029) compared to the aPTT group. After adjusting for several bleeding/thrombosis risk factors, 97.5% of FXa and 91.0% of aPTT patients reached therapeutic levels with comparable UFH duration and maximum dose. Moreover, in‐hospital mortality (2.5% vs. 3.1%, p = 0.842), major bleeding events (4.2% vs. 9.2%, p = 0.360), and thromboembolic events (21.8% vs. 10.1%, p = 0.151) remained without significant differences between FXa and aPTT cohorts. There was a high degree of variability in FXa ( r 2 = 0.20) and aPTT ( r 2 = 0.22) values for any given UFH dose.
Conclusions
No differences in frequency of bleeding or thromboembolic events were observed in this study between FXa versus aPTT cohorts after HM3 implantation. More longitudinal studies are warranted to determine whether or not one assay is superior to the other.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA.
- Center of Innovation and Outcomes Research, Department of Surgery, Columbia University, New York, New York, USA.
- Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
- Department of Anesthesiology, Columbia University Irving Medical Center, New York, New York, USA.
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
ORCID-Profile: Koji Takeda
Zitieren
APA
Feng, I., Kurlansky, P. A., Powley, T. R., Hynds, M. A., Yang, C. G., Eisenberger, A., Hastie, J. M., Sutherland, L. D., Yuzefpolskaya, M., Colombo, P. C., Sayer, G. T., Uriel, N. Y., Naka, Y., & Takeda, K. (2025). Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation. Artificial Organs. https://doi.org/10.1111/aor.14885
Vancouver
Feng I, Kurlansky PA, Powley TR, Hynds MA, Yang CG, Eisenberger A, et al. Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation. Artificial Organs. 2025. doi:10.1111/aor.14885
BibTeX
@article{Feng2025,
author = {Feng, Iris and Kurlansky, Paul A and Powley, Tanner R and Hynds, Melissa A and Yang, Christine G and Eisenberger, Andrew and Hastie, Jonathan M and Sutherland, Lauren D and Yuzefpolskaya, Melana and Colombo, Paolo C and Sayer, Gabriel T and Uriel, Nir Y and Naka, Yoshifumi and Takeda, Koji},
title = {Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation},
journal = {Artificial Organs},
year = {2025},
doi = {10.1111/aor.14885}
}
EUVIMED